cyrilzakka/clinical-trials huggingface dataset:
Real-time fMRI Neurofeedback for Treatment of Parkinson's Disease

The aim of the study is to train patients with Parkinson's Disease to increase activity in a brain area that is involved in the control of motor functions with the use of a technique called real-time fMRI neurofeedback (NF) along with regular physical exercise. This will be a randomised and controlled clinical trial to evaluate the benefits of a novel treatment. The investigators expect NF training along with physical exercise practise to better improve motor functions compared to physical exercise alone.


Eligibility Criteria:
Inclusion Criteria:

* People with Parkinson's Disease
* Hoehn and Yahr stages 1-3 of the disease

Exclusion Criteria:

* Patients with dementia or significant comorbidity
* those who fail the safety screening to go into an MRI scanner
* those who cannot travel to the University
The eDosette Pilot Study

Medication non-adherence can lead to serious health issues for older adults. This study is a four week study in older adults using a new device, the eDosette, which dispenses and records how one takes their medications, and subsequently makes this information available to the primary care team by the internet. This study aims to show that the eDosette can report how well a group of older adults living independently in the community are taking their medications (e.g. "medication adherence"). This study hopes to show that the eDosette intervention could play a role in medication adherence by improving conversations between older adults and primary care.


Eligibility Criteria:
Inclusion Criteria:

* age 65 and over
* taking five or more medications (including supplements)
* using or willing to use a blister pack or dosette
* currently managing their medications independently
* living independently
* English speaking

Exclusion Criteria:

* a documented diagnosis of mild cognitive impairment or dementia
* living in any form of assisted living facility
* currently palliative
* currently deemed medically unstable by their primary care team
Exercises and Performance Anxiety Among Young Instrumentalists.

The purpose of this study is to assess the impact of an original exercise program intended for students of the University of Music on dealing with stage fright and its psychophysical symptoms.

The study group covers students of a music university who play various musical instruments. Participants will be divided into the experimental and control groups. The study duration is scheduled to be 6 weeks. The control group will not have any intervention. The experimental group will undertake 45 mins exercise classes twice a week. Each exercise session will consist of an initial part (warm-up), a main part with exercises designed to strengthen the postural muscles and stretch the contracted muscle groups that are especially prone to pain in musicians (back and upper limbs), and a final part of calming and breathing exercises.

At the beginning and at the end of the study, participants of both groups will be asked to complete a Polish version of validated psychological questionnaires: Kenny Music Performance Anxiety Inventory-Revised, Ogińska-Bulik's \& Juczyński's Resiliency Assessment Scale (SPP-25), Musculoskeletal Pain Intensity and Interference Questionnaire for Musicians of the Polish Population (MPIIQM-P) and one original questionnaire assessing the stress level before, during and after a performance. All participants will also undergo physical examination. A measurement of the range of motion of trunk flexion in standing (cm) and the algometric measurement of the pain threshold (kg/cm2) of selected back muscles (trapezius muscles, upper and lower and levator scapula) on the right and left sides of the body. Algometric measurements will be made using the Pain Test FPX algometer Algometer (Wagner).

Statistical analysis. The variables will be coded and analyzed using the STATISTICA program. Baseline demographics will be compared between groups (independent t-tests, chi-square tests). Two-way mixed-model analyses of variance (ANOVA) will explore the effect of the exercise program on symptoms and anxiety.

Eligibility Criteria:
Inclusion Criteria:

* playing on a musical instrument for at least 5 years
* age 18 to 35
* consent to participate in the study
* participation in at least 8 meetings (exercise) within 6 weeks

Exclusion Criteria:

* current (last 3 months) locomotor injuries (fractures, sprains, dislocations), medical contraindications to exercise, confirmed by a medical opinion
* neurological and oncological diseases confirmed by a medical diagnosis
* previous spine surgeries, scoliosis confirmed by radiograph (\<10ᵒ Cobb)
* regular intake of muscle relaxants, painkillers, anti-inflammatory drugs, anti-depressants
* age under 18 or over 35
* no consent to participate in the study to participate in the study.
Effects of the Application of a Reflex Locomotion Program in the Neurological Hand

The recovery of the function of the hand is one of the most important aspects for patients who have suffered the consequences of neurological damage. Currently there are numerous therapeutic procedures aimed at rehabilitation that have scientific evidence such as restrictive therapy. However, dysfunction of the upper limb has an impact on the whole body that is not always taken into consideration.

The intervention of the stimulation of the reflex locomotion is carried out in this study in a sitting position in a conventional chair, an unorthodox posture in the usual treatment of Vojta therapy.

Description of the sitting posture: the back in axial extension with the shoulders located in front of the hips.

The elbows must be supported with the medial epicondyl in contact on a table, whose height is at the level of the end of the patient's sternum.

The forearms are placed prone with the palms facing the surface. In this position we place a rubber sphere 3 centimeters in diameter under the pisiform of one of the patient's wrists.

The reflex stimulation is performed by the passive pressure exerted by the weight of the wrist (pisiform) on the rubber sphere. Simultaneously the patient has to exert a slight pressure with the heel towards the ground with his foot. This foot will be the opposite of the wrist that has the sphere under the pisiform.

It is a cross-stimulation, that is, pisiform in one hand together with the load in the heel of the opposite side.

Alternating each diagonal 4 times, 5 minutes each. Total session 20 minutes, 2 times per day, every day according to degree of affectation

The duration of the study will depend on the degree of involvement: mild 2 weeks, moderate 3 months.

Eligibility Criteria:
Inclusion Criteria:

* Sequelae in the upper limb after neurological damage.
* Understanding and oral expression preserved.
* More than a year after the episode.
* Possibility of walking

Exclusion Criteria:

* Aphasia.
* Concomitant diseases: Diabetes and arthritis of the hand.
Performance of Two Toric Silicone Hydrogel Contact Lenses

Prospective study to evaluate the clinical performance of fanfilcon A toric contact lens and senofilcon A toric contact lens after two weeks of wear.

The aim of this prospective study is to evaluate the clinical performance of Avaira Vitality toric and ACUVUE OASYS® for ASTIGMATISM contact lenses after 2-weeks of wear in each pair.

Eligibility Criteria:
Inclusion Criteria:

* Is between 18 and 40 years of age (inclusive)
* Has had a self-reported visual exam in the last two years
* Is an adapted soft contact lens wearer
* Has a contact lens spherical prescription between +6.00 to - 9.00 (inclusive)
* Have no less than -0.75D of astigmatism and no more than -2.25 D in both eyes.
* Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye.
* Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses.
* Has clear corneas and no active ocular disease
* Has read, understood and signed the information consent letter.
* Patient contact lens refraction should fit within the available parameters of the study lenses.
* Is willing to comply with the wear schedule (at least 5 days per week, \> 8 hours/day assuming there are no contraindications for doing so).
* Is willing to comply with the visit schedule

Exclusion Criteria:

* Has a CL prescription outside the range of the available parameters of the study lenses.
* Has a spectacle cylinder less than -0.75D or more than -2.50 D of cylinder in either eye.
* Has a history of not achieving comfortable CL wear (5 days per week; \> 8 hours/day)
* Has contact lens best corrected distance vision worse than 20/25 (0.10 logMAR) in either eye.
* Presence of clinically significant (grade 2-4) anterior segment abnormalities
* Presence of ocular or systemic disease or need of medications which might interfere with contact lens wear.
* Slit lamp findings that would contraindicate contact lens wear such as:
* Pathological dry eye or associated findings
* Pterygium, pinguecula, or corneal scars within the visual axis
* Neovascularization \> 0.75 mm in from of the limbus
* Giant papillary conjunctivitis (GCP) worse than grade 1
* Anterior uveitis or iritis (past or present)
* Seborrheic eczema, Seborrheic conjunctivitis
* History of corneal ulcers or fungal infections
* Poor personal hygiene
* Has a known history of corneal hypoesthesia (reduced corneal sensitivity)
* Has aphakia, keratoconus or a highly irregular cornea.
* Has Presbyopia or has dependence on spectacles for near work over the contact lenses.
* Has undergone corneal refractive surgery.
* Is participating in any other type of eye related clinical or research study.
INSPIRE Continuation Post-Approval Study

To evaluate long-term BOS-free survival outcomes of the OCS™ Lung INSPIRE Trial patients.


Eligibility Criteria:
Inclusion Criteria:

* Participant in TransMedics OCS Lung System INSPIRE trial

Exclusion Criteria:

* None
Comparison of a Novel 22-gauge Core Biopsy Needle

The goal of this clinical research study is to compare the performance of a newly available needle with reverse bevel design (called the EchoTip® Procore™ needle) with standard needles to see which needle gives better diagnostic information for pancreatic lesions.

An endoscopic ultrasound-guided needle biopsy or FNA is a special endoscopic procedure used to sample lesions within or next to the digestive tract, including the pancreas. The needle is used to collect material for diagnosis. A special lighted, flexible tube called an endoscope is inserted through the mouth, into the stomach and small intestine. The endoscope also has an ultrasound probe at its tip which can be used to see the pancreas, which is located behind the stomach. The doctor will then use the ultrasound to guide the needle biopsy or FNA.

In this procedure, an average of 4 needle passes (needle sticks) is needed to collect enough tissue for diagnosis. However, the number of passes can be higher or lower, depending on the individual lesion and success of the needle passes.

If participant agrees to take part in this study, 2 different needles (the standard straight hollow-core needle and the new EchoTip® Procore™ needle) will be used to sample the pancreas lesion. Two (2) passes will be performed with each needle type and compared. If additional passes are needed for diagnosis, they will not be included in this study. After the first set of needle passes, the doctor may decide that more passes are needed.

Final test results will be taken from the diagnostic results from each needle pass. The results from both types of the needle will be included in the participant's medical record.

This is an investigational study. All needles used in this study are FDA approved and commercially available. Comparing the needles is investigational.

Up to 60 participants will take part in this study. All will be enrolled at MD Anderson.

Eligibility Criteria:
Inclusion Criteria:

1. Patient age 18 years and older.
2. All patients referred for EUS FNA of endoscopically accessible solid pancreatic lesions.

Exclusion Criteria:

1. Unable to obtain informed consent.
2. Unable to tolerate the procedure.
3. Women with known pregnancy at time.
4. Patient age less than 18 years of age.
5. Bleeding diathesis
6. Cystic pancreatic lesions
7. Lesion not accessible by EUS guided FNA
Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft

To investigate the presence of seconday of lymphoid organs in patients who underwent allogenic hematopoietic stem cell transplantation 15 to 45 years ago.

The goal aims to assess the development of seconday lymphoid organs given the fact that the absence of myeloablation these patients present a split chimerism between T lymphocytes and the other leucocytes. Thus, they may not be able to generate seconday lymphoid organs. Practically, whole body MRI is being used to visualise and quantify both mediastinal and intraabdominal lymph nodes. Delta will be compared with those obtained in healthy age-matched individuals. It is scheduled to include 15 patients and 15 controls.


Eligibility Criteria:
Inclusion Criteria:

* Patients with SCID transplanted 15-45 years ago

Exclusion Criteria:

* None
Effects of Coenzyme Q10 Supplementation on Oxidative Stress, Antioxidant Capacity, Inflammatory Responses, Fatigue Elimination, and Exercise Performance in Athletes

The aims of the study are 1) to compare the differences in plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances in athletes (i.e., soccer, and taekwondo players) and healthy non-athletes; 2) to investigate the relationship between plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances; 3) to explore the influence on plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances after 12 weeks of coenzyme Q10 intervention (150 mg/day and 300 mg/day).

The long-term high-amount and -intensity exercise training could cause oxidative damage, muscle impairment, inflammation and exercise fatigue to athletes easily. Such above conditions will affect the exercise performances and health of athletes. The aims of the study are 1) to compare the differences in plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances in athletes (i.e., soccer, and taekwondo players) and healthy non-athletes; 2) to investigate the relationship between plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances; 3) to explore the influence on plasma coenzyme Q10, oxidative stress, antioxidant capacity, muscle impairment, fatigue recovery, and inflammation and exercise performances after 12 weeks of coenzyme Q10 intervention (150 mg/day and 300 mg/day). Eventually, these results of this study can provide the information for the known to improve the oxidative stress, anti-oxidation and inflammation internal to the bodies of athletes for various competitions. As a consequence, the athletic performances can be further enhanced.

Eligibility Criteria:
Inclusion Criteria:

* Athletes (soccer and taekwondo players)

Exclusion Criteria:

* Antioxidant vitamins users
* Statins or Aspirin therapy.
Evaluation of Long-term Effect of Resonator Therapy on Parkinson's Disease (PD)

An extension study for subjects with prior participation in previous resonator studies using low level magnetic fields to treat some of the symptoms of idiopathic Parkinson's Disease.


Eligibility Criteria:
Inclusion Criteria:

* Prior participation in pico-tesla pilot studies: NCT00779155 \& NCT00863226
* Willing and able to abstain from partaking in non-essential new treatments for Parkinson's disease symptoms during the course of participation of the study.
* Will and able to abstain from all non-essential new medications that could affect PD and/or any of its associated symptoms for the duration of the study.
* Willing to notify the investigator right away of any changes in medication use or therapies that is prescribed and deemed necessary by the subjects physicians.
* Adequate contraceptive measures for female subjects
* Capable of giving full written informed consent

Exclusion Criteria:

* Not a participant in IRC#'s 07102 or 07021
* No active brain tumors, strokes, hydrocephalus
* Chronic pain not associated with PD
* Any other condition which might prevent subject from comfortably sitting for 1.5 hours
* Consumption of medications that can produce Parkinsonism type symptoms
* Major psychiatric disturbance
* Epilepsy
* HIv and other autoimmune disorders
* Cancer within last 2 years
* History of ECt
* Diabetic neuropathy
* Uncontrolled HTN
* Advanced Pulmonary disease
* Known heart conditions such as repetitive history of cardiac arrythmias
* Previous surgeries for PD
* Prosthetics comprised of ferrous materials
* Stents, only where there is also cardiac arrythmias, CHF, advanced valvular stenosis, unstable vital signs, extensive ischemic damage to heart muscle as a result of one or more heart attacks.
* Pacemakers
* Uncontrolled, unstable, or untreated medical illnesses which might potentially significantly affect the patient's health in the opinion of the investigator
* Consumption of more than 21 alcoholic drinks per week
* Pregnant, breast feeding or planning pregnancy
* Developmental disability or cognitive impairment
* Inability to maintain regular medication regime
* Inability to abstain from partaking in new non-essential PD tx., or medications
* Not willing to report physician mandated changes in medication and/or treatment
Carbetocin Versus Oxytocin for Prevention of Postcesarean Hemorrhage in Pregnancy With High Risk for PPH

Objective: study efficacy of carbtocin versus oxytocin for prevention postpartum hemorrhage in high risk pregnancy who undergo cesarean section

Randomized controlled clinical trial. Defined patient in two group. Primary outcome is evaluate additional drug use Secondary outcome is evaluated estimated blood loss, hemoglobin level

Eligibility Criteria:
Inclusion Criteria:

* previous history of postpartum hemorrhage
* polyhydramnios
* fetal macrosomia
* previous cesarean section
* grand multiparity
* intramural myoma
* chorioamnionitis
* prolonged premature rupture of membrane
* augmentation of labour

Exclusion Criteria:

* pregnancy induce hypertension
* on anticoagulant
* placenta previa or placenta percreta
Cardiovascular Acoustics and an Intelligent Stethoscope

The aim of the project is to develop an artificial intelligence software capable of analysing heart sounds to provide early diagnosis of a variety heart diseases at an early stage. Since the invention of the stethoscope by Laennec in 1816, the basic design has not changed significantly. Our software could be coupled with existing electronic stethoscopes to create an 'intelligent' stethoscope that could be used by healthcare assistants or practice nurses to screen for sound producing heart diseases. It could also be used at home by patients who would otherwise go undiagnosed.

The study investigators at Cambridge University Engineering Department (CUED) have developed a proof-of-concept AI algorithm to detect heart murmurs. However, in order to accurately detect the specific pathology and severity underlying the murmur, more heart sound recordings (matched with the ground truth from the patient's echocardiogram) are required. Patients presenting to one of the partner hospitals requiring an echocardiogram as part of their routine care will be invited to consent to this study. Participation will entail recording of a patient's heart sounds using an electronic stethoscope as well as collection of routine clinical data and a routine clinical echocardiogram at a single routine out patient visit.

This project will develop an AI algorithm which can be imported into a stethoscope to make it capable of automatically diagnosing any valve disease present and its severity. This will help GPs produce more accurate diagnoses, reduce costs by having fewer unnecessary referrals for echocardiogram, and produce more accurate diagnoses in countries where echocardiograms are not readily available due to their cost. Using a small sample of data as well as some which has been labelled by clinician auscultation, the team has created an award-winning AI algorithm capable of accurate detection of heart murmurs. However, in order to improve the accuracy and capability of this system more heart sound recordings from a range of diseases (matched with echocardiogram diagnosis) are required. The key to the success of this study will be to produce an AI algorithm that is more accurate than different grades of doctors at detecting the specific abnormality and severity underlying a heart murmur. This methodology will also provide a comprehensive study on acoustic characteristics of different heart sounds. So far all the acoustic characteristics of heart sounds taught to medical students are based on subjective opinion. This study will be able to objectively analyse these acoustic characteristics.

Eligibility Criteria:
Inclusion Criteria:

* Participant willing and able to give informed consent for participation in study
* Participant to undergo an echocardiogram as part of their routine assessment

Exclusion Criteria:

* Informed consent is not given
* New York Heart Association (NYHA) functional class = 4
Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics

A recently completed clinical drug interaction study of CP-945,598 with ketoconazole, a potent CYP3A inhibitor, showed that coadministration of CP-945,598 with ketoconazole results in an approximately 5-fold increase in CP-945,598 total exposure (AUC) and 4-fold increase in Cmax. Therefore, the sensitivity of CP-945,598 pharmacokinetics (PK) to less potent CYP3A inhibitors needs to be characterized to support labeling and registration.

Diltiazem is a known substrate and moderate mechanism-based inhibitor of the CYP3A enzyme system and was chosen as the moderate CYP3A inhibitor for this study as it is a clinically relevant medication likely to be prescribed concomitantly with CP-945,598 given the increased risk of hypertension and cardiovascular disease in the obese patient population.


Eligibility Criteria:
Inclusion Criteria:

* No clinically relevant abnormalities based upon medical history, physical exam, 12-lead ECG, and clinical lab tests
* Body Mass Index (BMI) \~ 27-40 kg/m2, inclusive
* Personally signed inform consent document

Exclusion Criteria:

* Evidence or history of significant acute or chronic disease
* Pregnant or nursing females
* Screening PR interval \> 220 msec
* Sitting blood pressure \<= 90 mmHg systolic or \<= 60 mmHg diastolic